{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:10:06Z","timestamp":1790935806728,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T00:00:00Z","timestamp":1520467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470357"],"award-info":[{"award-number":["81470357"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773102"],"award-info":[{"award-number":["81773102"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.neo.2018.03.003","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T22:32:29Z","timestamp":1522362749000},"page":"478-488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer"],"prefix":"10.1016","volume":"20","author":[{"given":"Juan","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hehui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiang","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2018.03.003_bb0005","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2018.03.003_bb0010","doi-asserted-by":"crossref","first-page":"13599","DOI":"10.18632\/oncotarget.7300","article-title":"ERbeta decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function","volume":"7","author":"Bado","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2018.03.003_bb0015","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ctrv.2012.12.001","article-title":"Targeting triple negative breast cancer: is p53 the answer?","volume":"39","author":"Turner","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.neo.2018.03.003_bb0020","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/carcin\/bgx071","article-title":"Intratumor heterogeneity predicts metastasis of triple-negative breast cancer","volume":"38","author":"Yang","year":"2017","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.neo.2018.03.003_bb0025","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1158\/2159-8290.CD-11-0320","article-title":"Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1","volume":"2","author":"Aarts","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.neo.2018.03.003_bb0030","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-009-0571-2","article-title":"Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome","volume":"122","author":"Murrow","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.neo.2018.03.003_bb0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.canlet.2016.09.024","article-title":"Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy","volume":"383","author":"Massey","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.neo.2018.03.003_bb0040","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","article-title":"Molecular Pathways: Targeting ATR in Cancer Therapy","volume":"21","author":"Karnitz","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neo.2018.03.003_bb0045","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.dnarep.2014.04.008","article-title":"DNA-PK phosphorylation of RPA32 Ser4\/Ser8 regulates replication stress checkpoint activation, fork restart, homologous recombination and mitotic catastrophe","volume":"21","author":"Ashley","year":"2014","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.neo.2018.03.003_bb0050","article-title":"BRCA1 inhibits AR\u2013mediated proliferation of breast cancer cells through the activation of SIRT1","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.neo.2018.03.003_bb0055","doi-asserted-by":"crossref","first-page":"7608","DOI":"10.18632\/oncotarget.3263","article-title":"BRCA1 regulates PIG3-mediated apoptosis in a p53-dependent manner","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2018.03.003_bb0060","article-title":"PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer","volume":"7","author":"Song","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.neo.2018.03.003_bb0065","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1159\/000443052","article-title":"Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer","volume":"38","author":"Zhu","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.neo.2018.03.003_bb0070","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1158\/1541-7786.MCR-11-0500","article-title":"WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis","volume":"10","author":"Garimella","year":"2012","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.neo.2018.03.003_bb0075","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2016.67.5991","article-title":"Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors","volume":"34","author":"Leijen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neo.2018.03.003_bb0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1039\/C6MD00439C","article-title":"ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells","volume":"8","author":"Ronco","year":"2017","journal-title":"MedChemComm"},{"key":"10.1016\/j.neo.2018.03.003_bb0085","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1158\/1538-7445.AM2013-2348","article-title":"Abstract 2348: Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients","volume":"73","author":"Jones","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.neo.2018.03.003_bb0090","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1158\/1535-7163.MCT-09-0519","article-title":"Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion","volume":"8","author":"Golding","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.neo.2018.03.003_bb0095","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1016\/j.bmcl.2004.09.060","article-title":"Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries","volume":"14","author":"Leahy","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.neo.2018.03.003_bb0100","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.neo.2018.03.003_bb0105","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1158\/1535-7163.MCT-13-0025","article-title":"Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy","volume":"12","author":"Guertin","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.neo.2018.03.003_bb0110","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.1073\/pnas.1002175107","article-title":"A minority of foci or pan-nuclear apoptotic staining of gammaH2AX in the S phase after UV damage contain DNA double-strand breaks","volume":"107","author":"de Feraudy","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neo.2018.03.003_bb0115","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","article-title":"Targeting WEE1 Kinase in Cancer","volume":"37","author":"Matheson","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.neo.2018.03.003_bb0120","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrm3115","article-title":"Mitotic catastrophe: a mechanism for avoiding genomic instability","volume":"12","author":"Vitale","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.neo.2018.03.003_bb0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.neo.2018.03.003_bb0130","doi-asserted-by":"crossref","first-page":"15160","DOI":"10.1073\/pnas.1505283112","article-title":"A haploid genetic screen identifies the G1\/S regulatory machinery as a determinant of Wee1 inhibitor sensitivity","volume":"112","author":"Heijink","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neo.2018.03.003_bb0135","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ctrv.2016.06.004","article-title":"Do platinum salts fit all triple negative breast cancers?","volume":"48","author":"Gerratana","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.neo.2018.03.003_bb0140","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1016\/j.celrep.2016.12.031","article-title":"Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities","volume":"17","author":"Sanjiv","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.neo.2018.03.003_bb0145","doi-asserted-by":"crossref","first-page":"8954","DOI":"10.1073\/pnas.1302927110","article-title":"Essential role for Cdk2 inhibitory phosphorylation during replication stress revealed by a human Cdk2 knockin mutation","volume":"110","author":"Hughes","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neo.2018.03.003_bb0150","doi-asserted-by":"crossref","first-page":"16090","DOI":"10.1073\/pnas.1005031107","article-title":"Chk1 promotes replication fork progression by controlling replication initiation","volume":"107","author":"Petermann","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neo.2018.03.003_bb0155","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/15384047.2017.1323582","article-title":"Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy","volume":"18","author":"Jin","year":"2017","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.neo.2018.03.003_bb0160","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","article-title":"Targeting the ATR\/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models","volume":"23","author":"Kim","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558618300800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558618300800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:05:30Z","timestamp":1761483930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558618300800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1476558618300800"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2018.03.003","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2018.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc. on behalf of SOCIETY.","name":"copyright","label":"Copyright"}]}}